Codiak BioSciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch CDAKQ and buy or sell other stocks, ETFs, and their options commission-free!

About CDAKQ

Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. 

CEO
Douglas E. Williams, PhD
CEODouglas E. Williams, PhD
Employees
Employees
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2015
Founded2015
Employees
Employees

CDAKQ Key Statistics

Market cap
58.90K
Market cap58.90K
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
559.58K
Average volume559.58K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$3.23
52 Week high$3.23
52 Week low
$0.0016
52 Week low$0.0016

Stock Snapshot

The current Codiak BioSciences(CDAKQ) stock price is $0.00, with a market capitalization of 58.9K.

On 2026-03-10, Codiak BioSciences(CDAKQ) shares started trading at —, with intraday highs of — and lows of —.

Trading volume for Codiak BioSciences(CDAKQ) stock has reached 0, versus its average volume of 559.58K.

Over the past 52 weeks, Codiak BioSciences(CDAKQ) stock has traded between a high of $3.23 and a low of $0.00.

Over the past 52 weeks, Codiak BioSciences(CDAKQ) stock has traded between a high of $3.23 and a low of $0.00.

People also own

Based on the portfolios of people who own CDAKQ. This list is generated using Robinhood data, and it’s not a recommendation.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.